Format

Send to

Choose Destination
Lancet Neurol. 2012 Jun;11(6):535-44. doi: 10.1016/S1474-4422(12)70133-3. Epub 2012 May 16.

Aquaporin 4 and neuromyelitis optica.

Author information

1
Academic Neurosurgery Unit, St George's, University of London, London, UK. mpapadop@sgul.ac.uk

Abstract

Neuromyelitis optica is an inflammatory demyelinating disorder of the CNS. The discovery of circulating IgG1 antibodies against the astrocyte water channel protein aquaporin 4 (AQP4) and the evidence that AQP4-IgG is involved in the development of neuromyelitis optica revolutionised our understanding of the disease. However, important unanswered questions remain--for example, we do not know the cause of AQP4-IgG-negative disease, how astrocyte damage causes demyelination, the role of T cells, why peripheral AQP4-expressing organs are undamaged, and how circulating AQP4-IgG enters neuromyelitis optica lesions. New drug candidates have emerged, such as aquaporumab (non-pathogenic antibody blocker of AQP4-IgG binding), sivelestat (neutrophil elastase inhibitor), and eculizumab (complement inhibitor). Despite rapid progress, randomised clinical trials to test new drugs will be challenging because of the small number of individuals with the disorder.

PMID:
22608667
PMCID:
PMC3678971
DOI:
10.1016/S1474-4422(12)70133-3
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center